by Dr. C.H. Weaver M.D. 5/2021
Precision cancer medicines and immunotherapy have transformed the outlook for patients with advanced melanoma leading to improved survival duration in recent years. But can immunotherapy be improved further? The results of a research report from the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting suggest that combining two immunotherapy drugs that act on different checkpoints, in this case PD-1 and LAG-3 are promising. When compared to standard anti-PD-1 “Checkpoint Inhibitor” monotherapy the combination of two immunotherapy medicines blocking different checkpoints delayed cancer progression in patients with previously untreated advanced melanoma.5
Opdivo is a precision cancer immunotherapy that belongs to a class of medicines called “checkpoint inhibitors.” Checkpoint inhibitors help to restore the body’s t cells in fighting cancer by releasing checkpoints that cancer uses to shut down the immune system. PD-1 and PD-L1 are proteins that inhibit certain types of immune responses and allow cancer cells to evade detection and attack by certain immune cells in the body. A checkpoint inhibitor can block the PD-1 and PD-L1 pathway and enhance the ability of the immune system to fight cancer. By blocking the binding of the PD-L1 ligand these drugs restore an immune cells’ ability to recognize and fight the lung cancer cells. Opdivo works by blocking PD-1 and is already approved for the treatment of melanoma because it prolongs survival and delays cancer recurrence.2-4 Immune checkpoint inhibitors have transformed melanoma treatment and improved survival rates for patients with advanced melanoma.
The lymphocyte-activation gene 3 (LAG-3) is a cell-surface molecule expressed on the immune systems effector T cells and regulatory T cells (Tregs) and functions to control T cell response, activation and growth. LAG-3 regulates an inhibitory immune checkpoint pathway that limits the activity of T cells, leading to an impaired ability to attack cancer cells. In the chronic presence of diseases like cancer, T cells exhibit progressive exhaustion that is characterized by the upregulation of inhibitory immune checkpoints such as PD-1 and LAG-3. Relatlimab is a LAG-3–blocking antibody that binds to LAG-3 on T cells, restoring the function of exhausted T cells. Studies suggest that blocking the LAG-3 pathway may restore T cell effector function and potentially promote an anti-cancer cell response. While LAG-3 and PD-1 are distinct immune checkpoint pathways, they may work together to improve effector T cell function.
About The RELATIVITY-047 Clinical Trial
In this clinical trial 714 patients with previously untreated, unresectable or metastatic melanoma received standard Checkpoint Inhibitor therapy with Opdivo (nivolumab) with or without relatlimab and directly compared.
- The median time until disease progression was significantly longer with the Opdivo and relatlimab combination compared with Opdivo alone – 10.1 v. 4.6 months.
- Progression-free survival rates at 1 year were 47.7% for patients receiving Opdivo and relatlimab compared with 36.0% for those receiving Opdivo alone.
Tagrisso® - Standard of Care for EGFR + Non Small Cell Lung Cancer
FLAURA study confirms Tagrisso as best initial treatment of EGFR + NSCLC - learn more about its role in NSCLC management
Treatment of Stage III B - IV Non-Small Cell Lung Cancer
Chemotherapy, biomarker testing and precision cancer medicines and immunotherapy are used to treat stage IIIB-IV NSCLC.
This is the first phase III study to validate inhibition of the LAG-3 immune checkpoint as a therapeutic strategy for patients with cancer. Our findings establish the LAG-3 pathway as the third immune checkpoint pathway in history, after CTLA-4 and PD-1, for which blockade has clinical benefit,” said lead author Evan J. Lipson, MD, an associate professor of oncology at the Johns Hopkins Kimmel Cancer Center and Bloomberg-Kimmel Institute for Cancer Immunotherapy in Baltimore.
These results demonstrate that a dual checkpoint inhibitor combination therapy with Opdivo and relatlimab is a potential novel treatment option for patients with previously untreated, unresectable, or metastatic melanoma. The manufacturer of Opdivo and relatlimab has recently stated that the combination delays melanoma recurrence better than treatment with Opdivo alone and data is being submitted to the U.S Food and Drug Administration.
Stay Current - Connect With Other Melanoma Patients
- Join The CancerConnect Community: Connect with others and receive regular updates
- Sign up for the Melanoma Newsletter Here
- Bristol Myers Squibb Announces RELATIVITY-047, a Trial Evaluating Anti-LAG-3 Antibody Relatlimab and Opdivo (nivolumab) in Patients with Previously Untreated Metastatic or Unresectable Melanoma, Meets Primary Endpoint of Progression-Free Survival
- Robert C, Long GV, Brady B, et al. Nivolumab in Previously Untreated Melanoma without BRAF Mutation. New England Journal of Medicine [early online publication]. November 16, 2014.
- Topalian SL, Sznol M, McDermott DF, et al. Survival, Durable Tumor Remission, and Long-Term Safety in Patients With Advanced Melanoma Receiving Nivolumab. Journal of Clinical Oncology [early online publication]. March 3, 2014. doi: 10.1200/JCO.2013.53.0105.
- Study Comparing Opdivo (nivolumab) to Chemotherapy in Treatment Naïve Advanced Melanoma Patients Marks First PD-1 Immune Checkpoint Inhibitor to Demonstrate a Survival Benefit in a Phase 3 Trial. Bristol-Myers Squibb website. Available here. Accessed November 17, 2014.